GERN - Geron slips as FDA reviews blood cancer therapy ahead of AdCom meeting
2024-03-12 11:00:48 ET
More on Geron
- Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA
- Geron Corporation (GERN) Q4 2023 Earnings Call Transcript
- Geron's Ideal Situation Appears To Be Already Priced In
- Seeking Alpha’s Quant Rating on Geron
- Historical earnings data for Geron